title: [Preventional intervention of myocardial interstitial fibrosis in murine myocardium with acute myocarditis].
abstract: OBJECTIVE
  To explore that whether intervening the fibrosis of heart interstitium in acute viral myocarditis is practical or not, and offer the experimental basis for clinic to choose the optimum period to intervene myocardial fibrosis.
  
  
  METHODS
  Animals were divided into three groups: myocarditis, myocarditis intervened by Losartan, and normal control. The death rate of every group was compared. HE staining and picrosirius red staining and circularly polarized light were used to investigate myocardial collagen expression. Cardiac output was measured by impedance differentiation, and cardiac index was computed to evaluate cardiac function.
  
  
  RESULTS
  The death rate of the group with Losartan was 75.0%, and that of the myocarditis group was 41.7%. The cardiac index of the group with the drug was 0.014 +/- 0.001 ml.min-1.cm2, the myocarditis group 0.019 +/- 0.004 ml.min-1.cm2, and the normal control 0.024 +/- 0.002 ml.min-1.cm2. The scanning area of collagen in the group with the drug was 2.06 +/- 0.77 mm, the myocarditis group 4.72 +/- 2.22 mm and the normal control 3.74 +/- 1.50 mm.
  
  
  CONCLUSIONS
  Collagen has increased in acute viral myocarditis, but its main role in this time is to repair the necrotic myocardium, and Losartan may block this process and make lesions develop. Therefore, the acute stage is not an practical period for intervening myocardial fibrosis in viral myocarditis.
authors.affiliation: Division of Cardio-Pulmonary Circulation, Fuwai Heart Hospital & Institute of Cardiovascular Disease, PUMC & CAMS, Beijing.
authors.forename: Z
authors.initials: Z
authors.lastname: Jing
authors.forename: X
authors.initials: X
authors.lastname: Cheng
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
mesh_terms: D000818:Animals; D003384:Coxsackievirus Infections; D029822:Enterovirus B, Human; D005355:Fibrosis / Q000517:prevention & control; D019808:Losartan / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009205:Myocarditis / Q000821:virology*; D009206:Myocardium / Q000473:pathology*; D011897:Random Allocation
chemical_list: D019808:Losartan